A Arjona-Sanchez1,2, S Rufian-Peña3,4, J M Sanchez-Hidalgo3,4, A Casado-Adam3,4, A Cosano-Alvarez3,4, J Briceño-Delgado3,4. 1. Unit of Oncologic and Pancreatic Surgery, University Hospital Reina Sofía, Menendez Pidal, 14004, Córdoba, Spain. alvaroarjona@hotmail.com. 2. CIBERehd, IMIBIC, University Hospital Reina Sofía, Córdoba, Spain. alvaroarjona@hotmail.com. 3. Unit of Oncologic and Pancreatic Surgery, University Hospital Reina Sofía, Menendez Pidal, 14004, Córdoba, Spain. 4. CIBERehd, IMIBIC, University Hospital Reina Sofía, Córdoba, Spain.
Abstract
BACKGROUND: The cytoreductive surgery (CRS) associated with hyperthermic intraperitoneal chemotherapy (HIPEC) has become the standard treatment in patients with carcinomatosis peritoneal from different origins. The use of a minimally invasive approach for this high complex procedure might be an alternative that provides them less morbidity and faster recovery with similar oncologic outcomes. METHODS: We describe the initial experience of CRS and HIPEC done via the laparoscopic route in patients with minimal peritoneal metastases in our Unit from March 2016 to January 2018. RESULTS: A total of eight patients were operated by this minimally invasive approach. The different diagnoses were low-grade pseudomyxoma peritonei (2), benign multicystic mesothelioma (2), primary epithelial ovarian carcinomatosis (2) and locally advanced colon carcinoma T4 (2). The median age was 54 (20-62) years, the median PCI was 3 (2-4), the median operative time was 287 min (240-360), complete cytoreduction CC0 was achieved in all the patients, and no major morbidity was observed. The median length of stay was 4.75 days (4-5). After a median follow-up of 9.5 months, no relapse has been observed. CONCLUSION: The results suggest that this minimally invasive approach for CRS and HIPEC is feasible and safe in a highly selected group of patients with peritoneal surface malignancies.
BACKGROUND: The cytoreductive surgery (CRS) associated with hyperthermic intraperitoneal chemotherapy (HIPEC) has become the standard treatment in patients with carcinomatosis peritoneal from different origins. The use of a minimally invasive approach for this high complex procedure might be an alternative that provides them less morbidity and faster recovery with similar oncologic outcomes. METHODS: We describe the initial experience of CRS and HIPEC done via the laparoscopic route in patients with minimal peritoneal metastases in our Unit from March 2016 to January 2018. RESULTS: A total of eight patients were operated by this minimally invasive approach. The different diagnoses were low-grade pseudomyxoma peritonei (2), benign multicystic mesothelioma (2), primary epithelial ovarian carcinomatosis (2) and locally advanced colon carcinoma T4 (2). The median age was 54 (20-62) years, the median PCI was 3 (2-4), the median operative time was 287 min (240-360), complete cytoreduction CC0 was achieved in all the patients, and no major morbidity was observed. The median length of stay was 4.75 days (4-5). After a median follow-up of 9.5 months, no relapse has been observed. CONCLUSION: The results suggest that this minimally invasive approach for CRS and HIPEC is feasible and safe in a highly selected group of patients with peritoneal surface malignancies.
Authors: Francisco C Muñoz-Casares; Sebastián Rufián; Álvaro Arjona-Sánchez; María J Rubio; Rafael Díaz; Ángela Casado; Álvaro Naranjo; Carlos J Díaz-Iglesias; Rosa Ortega; María C Muñoz-Villanueva; Jordi Muntané; Enrique Aranda Journal: Cancer Chemother Pharmacol Date: 2011-04-17 Impact factor: 3.333
Authors: Olivier Facy; Sophie Al Samman; Guy Magnin; Francois Ghiringhelli; Sylvain Ladoire; Bruno Chauffert; Patrick Rat; Pablo Ortega-Deballon Journal: Ann Surg Date: 2012-12 Impact factor: 12.969
Authors: E Facchiano; S Scaringi; R Kianmanesh; J M Sabate; B Castel; Y Flamant; B Coffin; S Msika Journal: Eur J Surg Oncol Date: 2007-07-20 Impact factor: 4.424
Authors: Thejus T Jayakrishnan; Anthony J Zacharias; Avishkar Sharma; Sam G Pappas; T Clark Gamblin; Kiran K Turaga Journal: World J Surg Oncol Date: 2014-08-21 Impact factor: 2.754
Authors: L Rodríguez-Ortiz; A Arjona-Sánchez; M Ibañez-Rubio; J Sánchez-Hidalgo; A Casado-Adam; S Rufián-Peña; J Briceño-Delgado Journal: Surg Endosc Date: 2020-04-23 Impact factor: 4.584
Authors: A Arjona-Sanchez; J Esquivel; O Glehen; G Passot; K K Turaga; D Labow; S Rufian-Peña; R Morales; K van der Speeten Journal: Surg Endosc Date: 2018-07-12 Impact factor: 4.584